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Abstract
Type 2 diabetes mellitus (T2D) is characterized mainly by insulin resistance 
and/or deficiency, presenting risk factors related to aging, hypercaloric diet and 
sedentary lifestyle. Hyperglycemia, a hallmark of T2D, contributes significantly to 
the production of reactive oxygen species (ROS), inducing oxidative stress and vari-
ous cellular and molecular changes in the body. As a consequence, several signaling 
pathways may be affected, mainly involving biological processes such as inflamma-
tion, DNA damage responses, antioxidant defense and metabolic changes. All these 
processes are relevant for the understanding of the pathogenesis of T2D, and also 
for the development of diabetic complications in chronic patients. Recently, com-
mon characteristics linking T2D to Alzheimer’s disease (AD) have been reported. 
The purpose of this chapter is to highlight the main processes associated with 
the disease, such as insulin signaling pathways, oxidative stress, mitochondrial 
dysfunction, DNA damage and repair and antioxidant defense. In addition, the 
molecular impact of nutritional interventions in patients with T2D will also be 
addressed, as will the molecular keystones linking T2D and AD. Recently, there is 
accumulated evidence indicating that the two diseases may share common signaling 
pathways that may be relevant to the etiopathogenesis of each of them.
Keywords: type 2 diabetes mellitus, insulin resistance, hyperglycemia,  
oxidative stress, DNA repair, reactive oxygen species (ROS),  
mitochondrial dysfunction, Alzheimer’s disease
1. Introduction
Diabetes mellitus is a metabolic disease that has a major impact on global public 
health, affecting more than 425 million people worldwide. The number of affected 
people tends to increase, mainly due to obesity, a risk factor closely related to type 
2 diabetes mellitus (T2D), the most common form of diabetes. Hyperglycemia is 
the most striking feature of the disease, which is the increase of blood glucose levels 
above those presented by healthy individuals. This could be the main consequence 
of poor insulin secretion, lack of insulin sensitivity in target tissues or the combina-
tion of both [1, 2].
The genetic predisposition may be one of the determinants that favor the 
susceptibility to T2D development. Several variants of genes and even epigenetic 
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modifications in histones and DNA methylation may influence the heritability of 
T2D [3, 4]. Due to the complexity of the interaction of different factors involved in 
this disease, genome-wide association studies (GWAS) have been performed in an 
attempt to identify genetic variants related to the increased risk of T2D.
In 2007, the first GWAS was performed in France in patients with T2D [5]; 
At present, at least 75 associated loci have been identified, including the TCF7L2 
transcription factor, which is the most common gene found, in addition to PPARG, 
KCNJ11, FTO, CDKN2A/2B, CDKAL1, IGFBP2 among others [6]. Since then, 
similar studies showed that the loci presenting greater association with T2D vary 
as regards the relative risk between different ethnicities [7]. Besides, these variants 
explain only a low percentage of the disease heritability, most of which are found 
in intergenic or intronic regions [6]. Furthermore, DNA methylation patterns may 
contribute to genetic susceptibility to T2D. There is evidence of an increased risk 
of T2D development associated with distinct methylation patterns in some loci [8], 
but this approach is still a major challenge for researchers.
While obesity and overweight have been considered an important cause of T2D, 
a poor diet and lack of physical activity significantly contribute to an increased risk 
of insulin resistance and T2D [9].
One of the greatest concerns regarding the poor glycemic control in patients 
with T2D is related to the micro and macrovascular complications of diabetes. 
Since the onset of T2D did not present specific acute symptoms, 50% of adults with 
T2D do not know that they have the disease [9]. Chronic hyperglycemia induces a 
series of complications, such as retinopathy, neuropathy and nephropathy. In a long 
term, the high blood glucose levels may also induce endothelial dysfunction, which 
contributes to the increased risk for the development of cardiovascular diseases.
2. Oxidative stress and mitochondrial dysfunction
Changes in glucose homeostasis represent a critical factor for the development of 
metabolic diseases. Normally, to maintain optimal levels of blood glucose, the pan-
creas secretes two hormones. In response to high glucose levels, pancreatic β cells 
secrete insulin, which promote the uptake of glucose by peripheral tissues, reduce 
gluconeogenesis and decrease glycogen and triglyceride breakdown. However, when 
glucose levels are reduced in the blood, α-cells release glucagon, which will reverse 
the above process.
Overall, insulin resistance is one of the main causes of disturbances in glucose 
homeostasis; when insulin receptors do not respond to the amount of insulin 
produced, the consequence is a deficiency of the body in the glucose uptake and 
absorption. As a compensatory mechanism, pancreatic β cells increase the release of 
insulin, but if the glucose levels remain high due to the inability of insulin to achieve 
body’s demand, it may occur the onset of T2D. Insulin resistance persists in patients 
since pre-diabetes, a stage in which individuals show glucose levels above the 
normal values, but not so high for the diagnosis of the disease. It should be mention 
that at this stage, a healthy nutritional style, physical exercises and weight control 
may allow the individuals to recover normal glucose levels.
At a long term, high levels of blood glucose can lead to a number of cellular and 
molecular changes in the body, especially due to the production of reactive oxygen 
species (ROS) [10]. It is well known that mitochondria are the main source of ROS; 
these highly dynamic organelles constantly undergo structural changes, respond-
ing rapidly to the physiological alterations in the environment. Exposure of cells 
to hyperglycemic conditions is associated with several mitochondrial alterations. 
There is evidence that the number and morphology of mitochondria are essential 
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for the maintenance of cellular function. Hyperglycemia in this context is reported 
as an inducer of glucose metabolism, which can promote several conformational 
changes in mitochondria, overload of the electron transport chain, leading to the 
overproduction of ROS, and mitochondrial dysfunction [11–14].
It has been reported [15] that patients with pre-diabetes presented an increase in 
the mitochondrial mass, suggesting that the initial increase in blood glucose levels 
may induce an adaptative response in order to increase mitochondrial biogenesis to 
maintain homeostasis. These results are associated with an increase in mitophagy, 
raising evidence that during pre-diabetes state there may be an elimination of 
compromised mitochondria in an attempt to reduce mitochondrial oxidative stress 
[15, 16].
ROS are normal byproducts of aerobic respiration, consisting of non-radicals, as 
hydrogen peroxide (H2O2) and free radicals, as hydroxyl radical (OH) and superox-
ide anion (O2
−). In normal situations, antioxidant enzymes (glutathione peroxidase, 
catalase and superoxide dismutase) are able to eliminate ROS and maintain the 
homeostasis of the organism. However, in a hyperglycemic state, the mitochondria 
electron transport chain becomes hyperactive, thus inducing an excessive produc-
tion of ROS that surpasses the antioxidant defense system [17]. The imbalance 
between the prooxidants and the antioxidant defense system lead to a condition 
called oxidative stress, where the reactive molecules can cause damage to lipids, 
proteins and nucleic acids [18].
Among DNA damage caused by ROS, the major oxidized base modifications 
generated are 8-oxoguanine (8-oxoG) and 8-oxodesoxyguanosine (8-oxodG), 
which could occur in both DNA and the nucleotide pool, the latter can be incor-
porated into the DNA during replication or repair [19, 20]. The repair of 8-oxoG 
in DNA is performed by the base excision repair mechanism (BER), in which the 
DNA glycosylase OGG1 recognizes the 8oxoG and together with APE1 enzyme, 
polymerase complex β and DNA ligase I promote DNA repair [21, 22]; the removal 
of 8-oxo-dG from the nucleotide pool is performed by the enzyme hMTH1 (human 
MutT homolog), which hydrolyses 8-oxo-dGTP to transport this molecule to the 
cytosol, preventing its incorporation into the DNA [23]. For different types of 
DNA lesions, other DNA repair processes, such as nucleotide excision, homologous 
recombination, non-homologous end-joining, and mismatch repair may also occur. 
In diabetes, there is evidence that DNA repair levels and activity of antioxidant 
enzymes are reduced [24, 25], as well as DNA damage levels and oxidized bases in 
these patients were found increased [26, 27].
The oxidative stress promoted by chronic hyperglycemia causes cellular damage 
mainly in the pancreatic β cells, which present low levels of antioxidant enzymes, 
and are more susceptible to damages caused by ROS. This stress is also responsible 
for releasing inflammatory mediators, which in turn culminate in a vicious cycle 
leading to β-cell dysfunction, insulin resistance and metabolic decline, which are 
critical for the development of T2D [28].
In diabetes, high glucose levels may also induce endoplasmic reticulum (ER) 
stress. Since the ER is the main responsible for protein maturation and folding, in 
particular proinsulin, in a hyperglycemic state, this molecule tends to be excessively 
synthesized and can overload the ER, leading to the accumulation of misfolded 
proteins, thus generating a stress condition. This stress may lead to the activation 
of the unfolded protein response pathway, which may restore ER homeostasis or 
induce cell death. The latter may lead to β-cell dysfunction, and consequently, to the 
reduction of insulin secretion and chronic hyperglycemia [28–31].
Several metabolic pathways are involved in insulin resistance and induction of 
inflammation and stress, including the JNK (JUN N-terminal kinase) and IKKβ 
(IκB kinase-β) pathways, both of them can be activated by ER stress [32]. IKKβ is 
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a protein responsible for mediating the activation of NF-κβ (nuclear factor-κB), 
which in turn stimulates the proinflammatory cytokines, TNF-α (tumor necrosis 
factor-alpha) and interleukin 1β (IL-1β), that can promote inhibition of the insulin 
receptor substrate (IRS) protein phosphorylation or reduce their transcriptional 
expression, compromising the insulin pathway and contributing to insulin resis-
tance [25, 28].
Obesity is another critical factor that results in oxidative stress and insulin resis-
tance [33], generating a chronic inflammatory condition in adipose tissue, causing 
the recurrent release of pro-inflammatory cytokines, such as those previously 
mentioned, in addition to interleukin 6 (IL-6), which together lead to pancreatic 
β-cell dysfunction, decreased insulin secretion, and consequently hyperglycemia 
and thus triggering T2D [28].
3. Insulin signaling pathway
The normal signalization of the insulin signaling pathway is vital and its 
dysregulation is implicated not only in T2D but also in diseases such as cancer, 
cardiovascular and neurodegenerative diseases. Changes in this signaling cascade as 
well as the consequences thereof, makes this pathway an important subject of study, 
considering its relevance in terms of age-related diseases.
Normally, the transport of glucose into the cells occurs through different 
intracellular signaling mechanisms performed in cascade, as shown in Figure 1. 
Firstly, insulin binds to its receptor, promoting tyrosine phosphorylation of IRS 
proteins, especially IRS-1 and 2. The tyrosine phosphorylation is critical for the 
Figure 1. 
Insulin/insulin-like growth factor signaling pathway.
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correct activation of the insulin pathway. Phosphorylation at serine or threonine 
residues is associated with the inhibition or even degradation of IRS proteins 
promoting downregulation of the pathway. This inhibitory effect over the pathway 
occurs normally via insulin-induced kinases as a way to keep the correct function 
of all proteins involved. However, some conditions as hyperglycemia, release of 
proinflammatory cytokines, oxidative stress (due to mitochondrial dysfunction), 
in addition to elevated fatty acids and ER stress can induce an increased serine or 
threonine phosphorylation, promoting the downregulation of insulin signaling and 
exacerbating the insulin resistance condition [2, 34, 35].
Thus, tyrosine phosphorylation of IRS proteins, further activate PI3K (phospha-
tidylinositol 3-kinase) protein [36, 37], promoting in particular the translocation 
of glucose transporter 4 (GLUT4) to the plasma membrane enabling the entrance 
of glucose into the cell [38]. Among the PI3K-associated downstream proteins, here 
we focus especially on Akt (alpha serine/threonine-protein kinase) [39, 40]. Once 
activated, Akt-regulated proteins have a key role in metabolism, glycogen synthesis, 
autophagy, growth, cell survival, transcription and protein synthesis [41]. Akt has 
been described as an important downregulator of GSK3α/β proteins. These proteins 
are strongly associated with the formation of amyloid beta and phosphorylation of 
tau protein, which are the main proteins involved in Alzheimer’s disease [42, 43]. 
Another important target of Akt are the FOXO (Forkhead box O) transcription 
factors, which regulates the expression of different genes related to gluconeo-
genesis, lipid metabolism, resistance to stress, DNA repair, cell growth, survival, 
differentiation, among others [41, 44, 45]. The kinase mTOR (mammalian target 
of rapamycin), responsible for regulating cell growth and metabolism, being a large 
sensor of nutrients and cellular energy, is also a target of Akt [46–48] and has a 
major role in the mechanism of longevity extension [49].
There is evidence that changes in the expression of growth factors, IRS proteins, 
IGF-1, AKT, mTOR, FOXO among others that result in downregulation of the 
insulin signaling pathway through nutritional restriction, for example, are impli-
cated in the resistance to stress, induction of autophagy, extension of longevity 
and reduction of aging-related diseases in different species, such as worms, flies, 
rats, mice and some primates [47, 50–55]. The inhibition of mTOR has been widely 
discussed as the main protein involved in the longevity extension. Metformin, a 
drug commonly used to control the glycemic levels in diabetics, is able to inhibit 
the activity of mTOR, via activation of AMPK, a protein with role in glycolysis, 
fatty acid oxidation, lipogenesis reduction, gluconeogenesis and protein synthesis 
[52, 56, 57]. AMPK is also important in mitochondrial biogenesis, since it activates 
PGC1α [58], which has the ability to stimulate the mitochondrial electron transport 
chain and suppress ROS levels, being essential in inducing the antioxidant defense 
system [49, 59].
4. Impact of nutritional interventions in diabetes care
Diabetes is a global health problem. Currently, the treatment of this disease 
has been carried out with medications, such as metformin, aiming to reduce the 
blood glucose levels, in an attempt to prevent a series of alterations in the cellular 
metabolism caused by chronic hyperglycemia. However, the success of treatments, 
in general, is limited, requiring other types of interventions (nutritional and 
regular physical activity, mainly) related to the patients’ lifestyle. The majority of 
patients with T2D present age between 40 and 59 years, which is critical for the 
disease [9] and in this phase, as in the subsequent stages, with the progression of 
the aging process, the protein homeostasis becomes increasingly compromised, 
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also accompanied by a reduction in the efficiency of the DNA repair system and the 
antioxidant defense, besides the organism as a whole, consequently leading to the 
accumulation of cellular damage [51, 58, 60, 61].
A great number of patients with T2D are overweight or obese. Changes in 
the lifestyle have been shown essential in controlling the levels of blood glucose. 
Additionally, it was reported that T2D patients submitted to a 7-day intervention to 
achieve adequate blood glucose levels led to a significant decrease in DNA damage 
levels [26]. In particular, some nutritional interventions, as well as caloric (CR) 
or protein restriction, have been shown to be very effective, not only for reducing 
blood glucose levels, but also for having very positive benefits in terms of increased 
life expectancy, as demonstrated in several model organisms [52, 54], in addition to 
reducing the incidence of aging-related diseases [62–64].
A major recruitment study known as CALERIE (Comprehensive Assessment 
of Long-term Effects of Reducing Intake of Energy) aimed to show the effects 
of caloric restriction in humans. It has already been shown that in a period of 
2 years, the CR is very efficient in improving insulin sensitivity [65], reducing 
inflammatory markers [66] and reducing oxidative stress [67]. Those features 
are especially significantly increased in patients with T2D, which would make 
this approach a valuable intervention for treatment of those patients. In fact, in a 
study performed in rhesus monkeys, from the 38 control animals, 16 developed 
high levels of blood glucose, becoming either prediabetic or diabetic. On the other 
hand, all the animals under caloric restriction did not present any impairment on 
glucose regulation [64], which may demonstrate the importance of this kind of 
intervention.
Although this approach has been widely discussed, the studies are still con-
troversial regarding the best diet composition for diabetic patients. It has been 
hypothesized that a high intake of proteins could influence the effects of a caloric 
restriction [68]. In fact, there is a study showing the efficiency of a protein restric-
tion intervention on reducing cancer incidence and extending lifespan regardless 
the intake of calories [69].
5. Susceptibility of T2D to Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive, continuous neurodegenerative disor-
der that affects large areas of the cerebral cortex and hippocampus. These abnor-
malities are usually detected for the first time in brain tissue involving the frontal 
and temporal lobes and then slowly advance to other areas of the neocortex at rates 
that vary considerably between individuals [70]. By 2018, an estimated 50 million 
people are living with dementia, with AD being the most prevalent form [71]. The 
main symptoms of AD result from the formation of beta-amyloid (Aβ) plaques 
and neurofibrillary tangles of the tau protein in the brain, which together lead to 
neuronal dysfunction and death, causing memory loss episodes which are charac-
teristic of the pathology [70, 72]. It has been reported that similar to the toxicity 
caused by Aβ aggregates in the brains of patients with AD, amyloid deposits in the 
pancreas occur in patients with diabetes, which may induce the death of pancreatic 
insulin-producing β cells [73].
Recently, several studies have narrowed the relationship between T2D and 
dementias [74, 75], suggesting that in addition to an increase in the incidence of 
dementia in T2D patients, a more rapid cognitive decline may also occur, includ-
ing a higher conversion rate of individuals who have mild cognitive impairment in 
patients with dementia [76–78]. This information has aroused interest in studying a 
possible association between T2D and dementia.
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Many hypotheses have been raised about the common features that involve the 
two pathologies and how these can be related to each other. It has been suggested 
that both diseases may share common signaling pathways, although molecular and 
cellular mechanisms still need elucidation. There is evidence that insulin resistance 
in the brain, including insulin pathway dysregulation, inflammatory processes, 
formation of advanced glycation products, as well as oxidative stress and mitochon-
drial dysfunction, may be implicated in the pathogenesis of AD and T2D [79].
Insulin, besides having an essential role as regulator of energy metabolism, 
also exerts a role in plasticity, survival and neuronal growth, as well as learning 
and memory processes, contributing to the improvement of cognitive functions; 
their absence has been associated with cognitive decline in patients with neuro-
logical and neurodegenerative diseases, such as AD [80–82]. In fact, it has been 
demonstrated that brains of patients with AD present altered insulin signaling 
[83]. Insulin receptors are found in the central nervous system (CNS) in large 
number and their impairment (hence the signaling cascade) may culminate 
in a number of alterations mainly involving PI3K, AKT and mTOR proteins. 
Abnormal expression of these and other proteins and the deregulation of this 
pathway may contribute to the formation of Aβ aggregates, neurofibrillary tangles 
by hyperphosphorylation of the tau protein [84], as well as the impairment of 
the autophagy process regulated by mTOR [75], whose hyperexpression has been 
related to T2D [85] and AD [86].
Thus, in the same way as T2D, AD is a disease related to less efficient molecular 
signaling in response to insulin, inflammation, oxidative stress, formation of 
advanced glycation end products and increased accumulation of DNA damage 
[87–89]. Thus, these characteristics suggest a connection between the two diseases.
The presence of higher levels of inflammation has already been described both in 
T2D and AD patients. In T2D there is a chronic inflammatory response localized in 
adipose tissue and characterized by the infiltration of immune system components, 
mainly macrophages, which release different proinflammatory cytokines such as 
TNF-α and IL-6 [90, 91]. Such cytokines may lead to insulin resistance by inducing 
cytokine signaling suppressors (SOCS), which participate in the degradation of 
IRS-1 and IRS-2 [92, 93]. In addition, these cytokines also activate stress response 
kinases, such as JNK and NF-κβ, which in turn act on the insulin receptor, inhibiting 
its tyrosine kinase activity, therefore culminating in insulin resistance [94, 95].
Similar inflammatory processes probably occur in the brain and peripheral 
tissues. Several studies have established the presence of inflammatory markers in 
the brains of patients with AD, including high levels of cytokines/chemokines [96]. 
In addition, inflammatory mediator levels in blood as TNF-α, IL-6 and IL-1b are 
increased in AD patients [97]. Thus, both in the brain and in peripheral tissues, 
chronic inflammation becomes harmful, leading to progressive damage to tissues 
and consequently triggering degenerative diseases.
There is evidence that insulin plays an important role in glucose regulation in 
the CNS, and its additional effects on neurons include metabolic, neurotrophic, 
neuromodulatory and neuroendocrine actions [98]. The presence of higher levels 
of inflammatory mediators in the CNS seems to stimulate the formation of beta-
amyloid oligomers and neurofibrillary tangles, which trigger the removal of insulin 
receptors in neurons, making this condition common in both T2D and AD, trigger-
ing progression of both diseases [89, 99] (Figure 2).
Besides, the lower sensitivity to insulin, in addition to being important for the 
progression of T2D, also appears to affect the expression and metabolism of Aβ 
proteins in the CNS, and consequently, an increase in oxidative stress condition 
[2, 100], which in turn, induces greater accumulation of Aβ oligomers [101] and 
the release of inflammatory mediators [88], as already mentioned. Thus, it seems 
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that all these processes are related to T2D and AD as a vicious cycle, leading to 
the development and progression of comorbidities in both diseases, being one 
of the consequences of hyperglycemia and the accumulation of Aβ oligomers, 
respectively.
However, both diseases seem to present less efficient DNA repair processes, 
which generate genomic instability and also cell death; this condition is closely 
related to the complications reported for patients with T2D, and also AD [24, 
102]. According to Xavier et al. [103], hyperglycemic T2D patients presented 
induction of DNA repair pathways, probably in response to higher levels of 
oxidative stress, but it remains to be elucidated whether the efficacy of repair 
pathways are normal in non-hyperglycemic T2D patients. In the case of AD, 
there is evidence that repair of DNA double strand breaks is less efficient [104], 
as well as base excision repair pathway [105], which would be detrimental to AD 
individuals, considering the relevance of DNA repair mechanisms for the DNA 
damage repair caused by ROS [106], and also by several kinds of endogenous and 
exogenous agents.
6. Conclusions
Insulin resistance is one of the main causes of disturbances in glucose homeo-
stasis. In patients with T2D, long term exposure to high levels of blood glucose can 
lead to a number of cellular and molecular changes in the body. In this context, 
hyperglycemia can promote several conformational changes in mitochondria, 
overload of the electron transport chain, leading to the overproduction of ROS, and 
mitochondrial dysfunction. Furthermore, the imbalance between the prooxidant 
and the antioxidant defense system lead to a condition of oxidative stress, where 
the reactive molecules can cause damage to lipids, proteins and nucleic acids. 
Interestingly, there is evidence that DNA repair levels and activity of antioxidant 
enzymes are reduced in T2D; in the opposite, DNA damage levels as well as oxidized 
bases in these patients were found increased. Insulin resistance has been also associ-
ated with several metabolic pathways and induction of inflammation and stress, 
including ER stress. Therefore, the normal signalization of the insulin pathway is 
vital and its dysregulation is implicated not only in T2D but also in other diseases 
such as cancer, cardiovascular and neurodegenerative diseases. In the brain, there is 
also evidence of insulin resistance and dysregulation of insulin pathway, generating 
inflammatory processes, as well as oxidative stress and mitochondrial dysfunction, 
all of them might be implicated in the pathogenesis of T2D and AD, thus linking the 
two diseases.
Figure 2. 
Relationship between increased levels of inflammatory factors and insulin sensitivity in both diseases, T2D and 
AD. Increased insulin resistance will lead to disease progression and the development of comorbidities in both 
T2D and AD.
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